Marie Linder

Om mig
Publikationer
CV
Populärvetenskap och samverkan

Om mig

Jag har en doktorsexamen i matematisk statistik från Stockholms Universitet
(SU). Min akademiska utbildning började på matematikerlinjen på SU. I maj
1992 presenterade jag examensarbetet ”Några statistiska metoder för
analys av tidsberoende bakgrundsdata, tillstånd efter viss tid och viss tid
till förändring, tillämpade på data från nedläggningen av
skolöverstyrelsen”. Efter min kandidatexamen fortsatte jag min akademiska
utbildning med doktorandstudier. Hösten 1997 presenterade jag min
licentiatavhandling ”Estimation of Bilinear Regression Models for Matrix
Type Data: Bilinear Least Squares and a Simple Alternative”. Min
doktorsavhandling blev färdig under 1998 och jag disputerade i januari 1999.
Titeln på min avhandling är ”Bilinear Regression and Second Order
Calibration”.
Förutom doktorandtjänsten på SU så arbetade jag även som föreläsare
och övningsassistent. Hösten 1998 började jag jobba på Astra som
biostatistiker. Första åren arbetade jag med kliniska prövningar för att
sedan succesivt arbeta mer och mer med djurstudier. På Astra fick jag
tillämpa mina teoretiska färdigheter på data från kliniska prövningar
och djurförsök. Våren 1999 gick Astra ihop med Zeneca och jag fortsatte
att arbeta på AstraZeneca. Hösten 2007 bytte jag arbete och började jobba
som statistiker på Socialstyrelsen, där arbetade jag med
socialtjänsteregistren. Efter 4 år, hösten 2011, började jag mitt jobb
som statistiker här på Centrumet för läkemedelsepidemiologi (CPE) vid
Karolinska Institutet.

Artiklar

Article: HEMASPHERE. 2026;10(5):e70373
Factors associated with response to rituximab in patients with immune thrombocytopenia.
Tsykunova G; Kristiansen EB; Tvedt THA; Frederiksen H; Christiansen CF; Linder M; Bahmanyar S; Ghanima W
Article: BRITISH JOURNAL OF DERMATOLOGY. 2026;194(3):481-488
The risk of venous thromboembolism in atopic dermatitis: a population-based cohort study
Ivert LU; Anveden-Berglind I; Gembert K; Eriksson J; Hernan Giunta D; Hagg D; Linder M
Article: SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY. 2025;60(6):526-535
Adult-onset inflammatory bowel disease and the risk of venous thromboembolism - a Swedish nationwide cohort study 2007-2021
Broms G; Forss A; Eriksson J; Askling J; Eriksson C; Halfvarson J; Linder M; Sun J; Westerlund E; Ludvigsson JF; Olen O
Article: JOURNAL OF NEURO-ONCOLOGY. 2025;173(2):383-395
Use of psychotropic medications among glioma patients in Denmark, Norway, Sweden, and Wales
Baxter SM; Bjorge T; Bjerkvig R; Cardwell C; Engeland A; Eriksson J; Habel L; Igland J; Klungsoyr K; Lunde A; Miletic H; Olesen M; Pottegard A; Reutfors J; Sharifian MJ; Linder M; Hicks B
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2024;205(4):1497-1507
Platelet response to romiplostim amongst patients with newly diagnosed, persistent, and chronic immune thrombocytopenia in routine clinical practice in Denmark, Sweden, and Norway
Christiansen CF; Risbo N; Ghanima W; Linder M; Bahmanyar S; Seesaghur A; Clouser M; Norgaard M; Sorensen HT
Article: JOURNAL OF THROMBOSIS AND THROMBOLYSIS. 2024;57(6):973-983
Comparison of rivaroxaban and low molecular weight heparin in the treatment of cancer-associated venous thromboembolism: a Swedish national population-based register study
Linder M; Ekbom A; Brobert G; Vogtlaender K; Balabanova Y; Becattini C; Carrier M; Cohen AT; Coleman CI; Khorana AA; Lee AYY; Psaroudakis G; Abdelgawwad K; Rivera M; Schaefer B; Giunta DH
Article: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2024;33(4):e5780
Consistency between the National Patient Register and the Swedish Cancer Register
Sakakibara S; Pazzagli L; Linder M
Article: CONTRACEPTION. 2024;131:110309
Characteristics and hormonal contraception use patterns of levonorgestrel 13.5 mg intrauterine device users in Sweden 2014-2016
Linder M; Schoendorf J; Pisa F; Schulze-Rath R; Cesta CE
Article: BMC MEDICINE. 2024;22(1):84
Estrogen-modulating treatment among mid-life women and COVID-19 morbidity and mortality: a multiregister nationwide matched cohort study in Sweden
Elenis E; Kallner HK; Karalexi MA; Haegg D; Linder M; Fall K; Papadopoulos FC; Skalkidou A
Article: PSYCHIATRY RESEARCH. 2023;326:115336
The association between exposure to clozapine, olanzapine, and quetiapine and the outcomes perimyocarditis and heart failure: A population-based cohort study
Clapham E; Reutfors J; Linder M; Brandt L; Sundstrom J; Boden R
Article: SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY. 2023;58(7):709-717
Identification of irritable bowel syndrome in the Swedish National Patient Register: a validation study
Tornkvist NT; Backman A-S; Linder M; Altman M; Simren M; Olen O; Tornblom H
Article: EUROPEAN JOURNAL OF EPIDEMIOLOGY. 2023;38(3):301-311
COVID-19 and comedications in atrial fibrillation-a case-control study in Stockholm
Bell M; Ekbom A; Linder M
Article: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2023;89(2):887-897
Bleeding events among patients concomitantly treated with direct oral anticoagulants and macrolide or fluoroquinolone antibiotics
Yagi T; Mannheimer B; Reutfors J; Ursing J; Giunta DH; Kieler H; Linder M
Article: EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES. 2022;8(5):577-587
Effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in atrial fibrillation: a Scandinavian population-based cohort study
Halvorsen S; Johnsen SP; Madsen M; Linder M; Sulo G; Ghanima W; Gislason G; Hohnloser SH; Jenkins A; Al-Khalili F; Tell GS; Ehrenstein V
Article: OBSTETRICS AND GYNECOLOGY. 2022;139(5):764-770
Method of Hormonal Contraception and Protective Effects Against Ectopic Pregnancy
Kopp-Kallner H; Linder M; Cesta CE; Chacon SS; Kieler H; Graner S
Article: SCIENTIFIC REPORTS. 2022;12(1):6245
Rationale and performances of a data-driven method for computing the duration of pharmacological prescriptions using secondary data sources
Pazzagli L; Liang D; Andersen M; Linder M; Khan AR; Sessa M
Article: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2022;31(2):235-246
Patient characteristics and safety outcomes in new users of ticagrelor and clopidogrel-An observational cohort study in Sweden
Linder M; Andersen M
Article: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2022;31(1):28-36
The use of uncertain exposure-A method to define switching and add-on in pharmacoepidemiology
Pazzagli L; Linder M; Reutfors J; Brandt L
Article: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2021;110(6):1570-1578
Lessons Learned Using Real-World Data to Emulate Randomized Trials: A Case Study of Treatment Effectiveness for Newly Diagnosed Immune Thrombocytopenia
McGrath LJ; Nielson C; Saul B; Breskin A; Yu Y; Nicolaisen SK; Kilpatrick K; Ghanima W; Christiansen CF; Bahmanyar S; Linder M; Eisen M; Wasser J; Altomare I; Kuter D; Sorensen HT; Kelsh M; Brookhart MA
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2021;195(3):456-465
Risk factors of hospitalisation for thrombosis in adults with primary immune thrombocytopenia, including disease-specific treatments: a French nationwide cohort study
Lafaurie M; Maquet J; Baricault B; Ekstrand C; Christiansen CF; Linder M; Bahmanyar S; Norgaard M; Sailler L; Lapeyre-Mestre M; Sommet A; Moulis G
Visa fler

Alla övriga publikationer

Conference publication: ACTA DERMATO-VENEREOLOGICA. 2025;105
THE RISK OF VENOUS THROMBOEMBOLISM IN ATOPIC DERMATITIS: A POPULATION-BASED COHORT STUDY
Ivert LU; Anveden-Berglind I; Gembert K; Eriksson J; Giunta DH; Hagg D; Linder M
Letter: DIABETES OBESITY & METABOLISM. 2024;26(11):5479-5482
Early uptake of semaglutide for type 2 diabetes in Scandinavia and characteristics of initiators in Denmark: A register-based drug utilization study
Rasmussen L; Andersen JH; Karlstad O; Giunta DH; Linder M; Furu K; Pottegard A
Review: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2024;33(5):e5799
Lessons learned from a multi-data source research collaboration: The mirabegron post-authorization safety study program
de Vogel S; Seeger JD; Arana A; Margulis AV; McQuay LJ; Perez-Gutthann S; Hallas J; Kristiansen NS; Linder M; Odsbu I; Suehs B; Xu Y; Uribe C; Appenteng K; Robinson NJ
Review: JOURNAL OF HEALTH POPULATION AND NUTRITION. 2023;42(1):122
A global systematic overview of socioeconomic factors associated with antidiabetic medication adherence in individuals with type 2 diabetes
Studer CM; Linder M; Pazzagli L
Meeting abstract: ANNALS OF ONCOLOGY. 2022;33(7):S1272-S1273
Swedish national population-based study of direct oral anticoagulants and low molecular weight heparin treatment for thromboembolism in cancer patients: The OSCAR SWE study
Linder M
Conference publication: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2022;31:45-46
Method of hormonal contraception and protective effects against ectopic pregnancy: A population-based register study
Linder M; Cesta C; Kallner HK; Chacon SS; Graner S
Conference publication: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2022;31:313
The completeness of the Swedish national patient register in terms of cancer diagnoses
Sakakibara S; Pazzagli L; Linder M
Preprint: RESEARCH SQUARE. 2022
Covid-19 and comedications in atrial fibrillation – a case-control study in Stockholm
Bell M; Ekbom A; Linder M
Conference publication: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2021;30:365
The use of uncertain exposure - A method to define switching and add-on in pharmacoepidemiology
Pazzagli L; Linder M; Reutfors J; Brandt L
Conference publication: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2021;30:386
Use of non-insulin antidiabetic drugs in children and young adults a Scandinavian drug utilization study from 2010-2019
Jensen HCK; Rasmussen L; Furu K; Karlstad O; Linder M; Cesta CE; Pottegard A
Conference publication: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2021;30:85
Cardiovascular risk in users of mirabegron relative to users of antimuscarinic treatments for overactive bladder: Findings from a non-interventional, real-world data safety study
Hoffman V; Hallas J; Linder M; Margulis AV; Suehs BT; Arana A; Enger C; Horter L; Odsbu I; Olesen M; Perez-Gutthann S; Xu Y; Kristiansen NS; Appenteng K; de Vogel S; Seeger JD
Editorial: BRITISH JOURNAL OF DERMATOLOGY. 2021;185(1):11-12
Using epidemiological methods to quantify the risk of serious infections in children with atopic dermatitis
Linder M
Conference publication: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2020;29:84-85
Occurrence of metabolic risk factors stratified by psoriasis severity: A Swedish population-based matched cohort study
Hagg D; Linder M; Hajiebrahimi M; Song C; Andersson TM-L; Villacorta R
Conference publication: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2020;29:608-609
Adverse bleeding events among patients concomitantly treated with direct anti-coagulants and antibiotics within a Swedish nationwide cohort
Yagi T; Kieler H; Reutfors J; Mannheimer B; Linder M
Conference publication: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2020;29:465
A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder
Phiri K; Hallas J; Linder M; Margulis A; Suehs B; Arana A; Bahmanyar S; Enger C; Horter L; Odsbu I; Olesen M; Perez-Gutthann S; Kristiansen NS; Appenteng K; de Vogel S; Seeger J
Conference publication: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2020;29:176-177
Feasibility of studying the use of tissue-agnostic cancer drugs in population-based European health databases
Garcia de Albeniz X; Riera Guardia N; Gutierrez L; Bahmanyar S; Blin P; Droz C; Heinig M; Linder M; Moore N; Schulze-Rath R; Sultana J; Trifiro G; Zhang WW; Zong J
Conference publication: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2020;29:310-311
Societal impact for patients with psoriasis: A nationwide Swedish register study
Linder M
Conference publication: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2020;29:608
A multinational European study of anaphylaxis among recipients of intravenous Iron
Gutierrez L; Blin P; Dress J; Droz-Perroteau C; Ehrenstein V; Franzoni C; Kollhorst B; Lassalle R; Linder M; Moore N; Odsbu I; Overbeek J; Perez-Gutthann S; Schink T; Rascher K; Rasouliyan L; Reinold J; Rothman KJ; Saigi-Morgui N; Schaller M; Smits E; Timmer A; Toft G; von Gersdorff G; Fortuny J
Conference publication: EUROPEAN HEART JOURNAL. 2019;40:2088
Comparative effectiveness and safety of non-vitamin K oral anticoagulants and warfarin in non-valvular atrial fibrillation - a cohort study in 3 Nordic countries
Johnsen S; Madsen M; Linder M; Sulo G; Ghanima W; Gislason G; Halvorsen S; Hohnloser SH; Jenkins A; Al-Khalili F; Tell GS; Ehrenstein V
Conference publication: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2019;28:104-105
Eye color and risk of ocular melanoma in patients with glaucoma - a Swedish register study combining data from the Swedish police Authority's register on passport applications and National Health Registers
Hagg D; Berglind IA; Kieler H; Linder M; Odsbu I
Visa fler

Om mig

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI